DGAP-News: Raptor Pharmaceutical Corp. Announces EMA Validation of Marketing Authorization Application for RP103 for the Treatment of Nephropathic Cystinosis
Raptor Pharmaceutical Corp.
26.03.2012 12:30
—————————————————————————
FDA NDA Submission Planned in March 2012
NOVATO, Calif., 2012-03-26 12:30 CEST (GLOBE NEWSWIRE) —
Raptor Pharmaceutical Corp. (–Raptor– or the –Company–) (Nasdaq:RPTP),
announced that the European Medicines Agency (–EMA–) has determined that
Raptor–s Marketing Authorization Application (–MAA–) for its investigational
drug candidate, RP103 for the potential treatm
